Altered Functionality of Anti-Bacterial Antibodies in Patients with Chronic Hepatitis C Virus Infection

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Lamontagne, Anne ^a   Long, Ronald E ^a   Comunale, Mary Ann ^a   Hafner, Julie ^b   Rodemich Betesh, Lucy ^a   Wang, Mengjun ^a   Marrero, Jorge ^c   Di Bisceglie, Adrian M ^d   Block, Timothy ^a   Mehta, Anand ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b Immunotope Inc   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d Saint Louis University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BACTERIUM ANTIBODY; COMPLEMENT; IMMUNOGLOBULIN G ANTIBODY; INTERFERON;

ADULT; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; CYTOLYSIS; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; GLYCOSYLATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE FLORA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PROTEIN FUNCTION; TARGET CELL DESTRUCTION;

ANTIBODIES, BACTERIAL; COMPLEMENT SYSTEM PROTEINS; FEMALE; GLYCOSYLATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYSACCHARIDES;

BACTERIA (MICROORGANISMS); ENTEROBACTERIACEAE; HEPATITIS C VIRUS;

EID: 84878643958     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064992     Document Type: Article

References (43)

1. Alter MJ, (1997) Epidemiology of hepatitis C. Hepatology. 26: 62S-65S.
2. Hoofnagle JH, (1997) Hepatitis C: the clinical spectrum of disease. Hepatology 26: 15S-20S.
3. Di Bisceglie AM, (1997) Hepatitis C and hepatocellular carcinoma. Hepatology 26: 34S-38S.
4. Iredale JP, (2007) Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 117: 539-548.
5. Friedman SL, (2007) A deer in the headlights: BAMBI meets liver fibrosis. Nat Med 13: 1281-1282.
6. Mehal WZ, Iredale J, Friedman SL, (2011) Scraping fibrosis: expressway to the core of fibrosis. Nat Med 17: 552-553.
7. Hernandez-Gea V, Friedman SL, (2011) Pathogenesis of liver fibrosis. Annual review of pathology 6: 425-456.
8. Jiao J, Friedman SL, Aloman C, (2009) Hepatic fibrosis. Current opinion in gastroenterology 25: 223-229.
9. Friedman SL, (2008) Hepatic fibrosis - overview. Toxicology 254: 120-129.
10. Friedman SL, (2007) Liver fibrosis: from mechanisms to treatment. Gastroenterologie clinique et biologique 31: 812-814.
11. Friedman SL, Rockey DC, Bissell DM, (2007) Hepatic fibrosis 2006: report of the Third AASLD Single Topic Conference. Hepatology 45: 242-249.
12. Nolan JP, (1989) Intestinal endotoxins as mediators of hepatic injury-an idea whose time has come again. Hepatology 10: 887-891.
13. Jirillo E, Caccavo D, Magrone T, Piccigallo E, Amati L, et al. (2002) The role of the liver in the response to LPS: experimental and clinical findings. J Endotoxin Res 8: 319-327.
14. Nolan JP, (1981) Endotoxin, reticuloendothelial function, and liver injury. Hepatology 1: 458-465.
15. Gioannini TL, Teghanemt A, Zhang D, Prohinar P, Levis EN, et al. (2007) Endotoxin-binding proteins modulate the susceptibility of bacterial endotoxin to deacylation by acyloxyacyl hydrolase. J Biol Chem 282: 7877-7884.
16. Shao B, Lu M, Katz SC, Varley AW, Hardwick J, et al. (2007) A host lipase detoxifies bacterial lipopolysaccharides in the liver and spleen. J Biol Chem 282: 13726-13735.
17. Mehta AS, Long RE, Comunale MA, Wang M, Rodemich L, et al. (2008) Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis. J Virol 82: 1259-1270.
18. Galili U, (1993) Evolution and pathophysiology of the human natural anti-alpha-galactosyl IgG (anti-Gal) antibody. Springer Semin Immunopathol 15: 155-171.
19. Galili U, Anaraki F, Thall A, Hill-Black C, Radic M, (1993) One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody. Blood 82: 2485-2493.
20. Galili U, Rachmilewitz EA, Peleg A, Flechner I, (1984) A unique natural human IgG antibody with anti-alpha-galactosyl specificity. J Exp Med 160: 1519-1531.
21. Balagopal A, Philp FH, Astemborski J, Block TM, Mehta A, et al. (2008) Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology. 135: 226-233.
22. Kaneko Y, Nimmerjahn F, Ravetch JV, (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313: 670-673.
23. Galili U, LaTemple DC, Radic MZ, (1998) A sensitive assay for measuring alpha-Gal epitope expression on cells by a monoclonal anti-Gal antibody. Transplantation 65: 1129-1132.
24. Hamadeh RM, Jarvis GA, Galili U, Mandrell RE, Zhou P, et al. (1992) Human natural anti-Gal IgG regulates alternative complement pathway activation on bacterial surfaces. J Clin Invest 89: 1223-1235.
25. Posekany KJ, Pittman HK, Bradfield JF, Haisch CE, Verbanac KM, (2002) Induction of cytolytic anti-Gal antibodies in alpha-1,3-galactosyltransferase gene knockout mice by oral inoculation with Escherichia coli O86:B7 bacteria. Infect Immun 70: 6215-6222.
26. Mehta A, Block TM, (2008) Fucosylated glycoproteins as markers of liver disease. Dis Markers 25: 259-265.
27. Papp M, Norman GL, Vitalis Z, Tornai I, Altorjay I, et al. (2010) Presence of anti-microbial antibodies in liver cirrhosis-a tell-tale sign of compromised immunity? PLoS ONE 5: e12957.
28. Sandler NG, Koh C, Roque A, Eccleston JL, Siegel RB, et al. (2011) Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 141: 1220-1230, 1230 e1221-1223.
29. Galili U, Wang L, LaTemple DC, Radic MZ, (1999) The natural anti-Gal antibody. Subcell Biochem 32: 79-106.
30. Wormald MR, Rudd PM, Harvey DJ, Chang SC, Scragg IG, et al. (1997) Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides. Biochemistry 36: 1370-1380.
31. Nimmerjahn F, Anthony RM, Ravetch JV, (2007) Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc Natl Acad Sci U S A 104: 8433-8437.
32. Potter BJ, Trueman AM, Jones EA, (1973) Serum complement in chronic liver disease. Gut 14: 451-456.
33. LaTemple DC, Henion TR, Anaraki F, Galili U, (1996) Synthesis of alpha-galactosyl epitopes by recombinant alpha1,3galactosyl transferase for opsonization of human tumor cell vaccines by anti-galactose. Cancer Res 56: 3069-3074.
34. Parker W, Lin SS, Yu PB, Sood A, Nakamura YC, et al. (1999) Naturally occurring anti-alpha-galactosyl antibodies: relationship to xenoreactive anti-alpha-galactosyl antibodies. Glycobiology 9: 865-873.
35. Parker W, Stitzenberg KB, Yu PB, Pratt VS, Nakamura YC, et al. (2001) Biophysical characteristics of anti-Gal(alpha)1-3Gal IgM binding to cell surfaces: implications for xenotransplantation. Transplantation 71: 440-446.
36. Yu PB, Holzknecht ZE, Bruno D, Parker W, Platt JL, (1996) Modulation of natural IgM binding and complement activation by natural IgG antibodies: a role for IgG anti-Gal alpha1-3Gal antibodies. J Immunol 157: 5163-5168.
37. Block TM, Comunale MA, Lowman M, Steel LF, Romano PR, et al. (2005) Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci U S A 102: 779-784.
38. Comunale MA, Lowman M, Long RE, Krakover J, Philip R, et al. (2006) Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. Journal of Proteome Research 6: 308-315.
39. Guile GR, Rudd PM, Wing DR, Prime SB, Dwek RA, (1996) A rapid high-resolution high-performance liquid chromatographic method for separating glycan mixtures and analyzing oligosaccharide profiles. Anal Biochem 240: 210-226.
40. Rudd PM, Dwek RA, (1997) Rapid, sensitive sequencing of oligosaccharides from glycoproteins. Curr Opin Biotechnol 8: 488-497.
41. Rudd PM, Guile GR, Kuster B, Harvey DJ, Opdenakker G, et al. (1997) Oligosaccharide sequencing technology. Nature 388: 205-207.
42. Rudd PM, Mattu TS, Zitzmann N, Mehta A, Colominas C, et al. (1999) Glycoproteins: rapid sequencing technology for N-linked and GPI anchor glycans. Biotechnol 16: 1-21.
43. Rudd PM, Endo T, Colominas C, Groth D, Wheeler SF, et al. (1999) Glycosylation differences between the normal and pathogenic prion protein isoforms. Proc Natl Acad Sci U S A 96: 13044-13049.